A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness

PHASE3CompletedINTERVENTIONAL
Enrollment

578

Participants

Timeline

Start Date

May 22, 2025

Primary Completion Date

June 29, 2025

Study Completion Date

June 29, 2025

Conditions
Ocular Redness
Interventions
DRUG

BTOS-HA

Brimonidine tartrate ophthalmic solution 0.025% with sodium hyaluronate (BTOS-HA) administered as 1 topical ocular drop instilled into each eye (OU), 4 times daily (QID), approximately 4 hours apart

DRUG

Lumify®

Brimonidine tartrate ophthalmic solution 0.025%, administered as 1 topical ocular drop instilled into each eye (OU), 4 times daily (QID), approximately 4 hours apart

Trial Locations (11)

16066

Site 112, Cranberry Township

27529

Site 108, Garner

28150

Site 107, Shelby

37167

Site 105, Smyrna

38119

Site 101, Memphis

40206

Site 106, Louisville

60062

Site 111, Northbrook

66762

Site 109, Pittsburg

91204

Site 102, Glendale

92663

Site 104, Newport Beach

01810

Site 103, Andover

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY